Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 1, 2014, Pages 79-86

  Xu, Wei Qun ^a   Zhang, Ling Yan ^a   Chen, Xue Ying ^a   Pan, Bin Hua ^a   Mao, Jun Qing ^a   Song, Hua ^a   Li, Jing Yuang ^a   Tang, Yong Min ^a  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute lymphoblastic leukemia; Childhood; Creatinine clearance; Elimination delay; High dose methotrexate; Non Hodgkin lymphoma

Indexed keywords

CREATININE; FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHILD; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84892820546     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2319-2     Document Type: Article

References (19)

1. Pui CH (2010) Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 109:777-787
2. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C (1998) Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol 37:277-284
3. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667-1672
4. Xu W, Tang Y, Song H, Shi S, Yang S (2007) Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol 29:688-693
5. Takami M, Kuniyoshi Y, Oomukai T, Ishida T, Yamano Y (1995) Severe complications after high-dose methotrexate treatment. Acta Oncol 34:611-612
6. Borsi JD, Revesz T, Schuler D (1987) Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 19:261-264
7. Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, Civin C, Graham M, Mahoney D, Munoz L, et al. (1989) Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 7:1539-1544
8. Seidel H, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slordal L (1997) On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia. Leuk Res 21:429-434
9. Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro R, Rubnitz J, Pui CH, Evans WE, Relling MV (2013) Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72:369-378
10. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS (2011) Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit 33:99-107
11. Kapoor G, Sinha R, Abedin S (2012) Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer 59:448-453
12. Skarby T, Jonsson P, Hjorth L, Behrentz M, Bjork O, Forestier E, Jarfelt M, Lonnerholm G, Hoglund P (2003) High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 51:311-320
13. Pizzo PA, Poplack DG (2006) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, Philadelphia
14. Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33:677-684
15. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J (2008) Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer 51:380-386
16. Ye H, Gu L, Chen J (2001) High-dose methotrexate therapy in children with acute lymphoblastic leukemia. Chin J Hematol 22:385-386
17. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, Rost M, Zintl F (2003) Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40:348-354
18. Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1:359-362
19. Joannon P, Oviedo I, Campbell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43:17-22